Table of Contents
Trial overview
This article covers one clinical trial of Avacincaptad Pegol in people with geographic atrophy.[1] The study was titled “An Open-Label Extension Study for Patients who Previously Completed Study ISEE2008 (GATHER2).”[1] It was a completed Phase 3 interventional trial with 280 participants.[1]
Who participated
The trial focused on patients with geographic atrophy, which is the condition listed in the study record.[1] It included people who had already completed Study ISEE2008 (GATHER2) through the Month 24 visit while on study treatment, either Avacincaptad pegol or Sham.[1] This means the study was a follow-up for patients already involved in earlier research.[1]
Study design and phase
This was an open-label extension study, which means it continued research after the earlier trial and did not hide the treatment assignment from patients or researchers.[1] The study was in Phase 3, a later stage of clinical testing that usually helps researchers collect more safety and outcome data in a larger group of patients.[1] The trial was completed.[1]
What was measured
The main outcome was AEs, short for adverse events.[1] Adverse events are any unwanted medical problems that happen during a study, whether or not they are caused by the study treatment.[1] The stated goal was to assess the long-term safety of monthly intravitreal administration of Avacincaptad pegol in patients with GA who had completed the earlier study.[1]
Key points for patients
This trial was not a first-time study of Avacincaptad Pegol.[1] Instead, it followed patients from an earlier study to learn more about safety over a longer time.[1] The record also lists fluorescein as an intervention, but the main study focus was the safety follow-up of Avacincaptad pegol in geographic atrophy.[1]
